Shield Therapeutics (STX) Competitors GBX 2.72 -0.14 (-4.74%) As of 03:59 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock STX vs. ELX, TAO, APC, DGI, IDEA, VLG, DNL, EAH, PXS, and CHLLShould you be buying Shield Therapeutics stock or one of its competitors? The main competitors of Shield Therapeutics include El Oro (ELX), TAO Alpha (TAO), Apc Technology Group (APC), DG Innovate (DGI), Ideagen (IDEA), Venture Life Group (VLG), Diurnal Group (DNL), ECO Animal Health Group (EAH), Provexis (PXS), and Chill Brands Group (CHLL). Shield Therapeutics vs. Its Competitors El Oro TAO Alpha Apc Technology Group DG Innovate Ideagen Venture Life Group Diurnal Group ECO Animal Health Group Provexis Chill Brands Group El Oro (LON:ELX) and Shield Therapeutics (LON:STX) are both small-cap computer hardware companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Is ELX or STX more profitable? El Oro has a net margin of 0.00% compared to Shield Therapeutics' net margin of -173.43%. El Oro's return on equity of 0.00% beat Shield Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets El OroN/A N/A N/A Shield Therapeutics -173.43%-470.50%-47.85% Do institutionals and insiders hold more shares of ELX or STX? 11.9% of Shield Therapeutics shares are owned by institutional investors. 62.2% of Shield Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has higher valuation and earnings, ELX or STX? El Oro has higher earnings, but lower revenue than Shield Therapeutics. Shield Therapeutics is trading at a lower price-to-earnings ratio than El Oro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEl Oro-£7.25M0.00N/A-£2.50N/AShield Therapeutics£20.92M1.28-£36.28M-£3.88-0.70 Does the media favor ELX or STX? In the previous week, El Oro's average media sentiment score of 0.00 equaled Shield Therapeutics'average media sentiment score. Company Overall Sentiment El Oro Neutral Shield Therapeutics Neutral SummaryEl Oro and Shield Therapeutics tied by winning 4 of the 8 factors compared between the two stocks. Get Shield Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for STX and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STX vs. The Competition Export to ExcelMetricShield TherapeuticsDrug Manufacturers IndustryMedical SectorLON ExchangeMarket Cap£26.79M£2.16B£5.54B£2.96BDividend YieldN/A2.92%5.39%5.02%P/E Ratio-0.704.1726.17144.10Price / Sales1.28550.22413.55257,096.93Price / Cash6.3610.3536.1327.97Price / Book49.6112.288.025.29Net Income-£36.28M£21.15B£3.15B£5.90B7 Day Performance-6.38%2.45%1.48%0.23%1 Month Performance12.14%5.14%3.66%4.86%1 Year Performance58.68%2.78%34.68%80.47% Shield Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STXShield TherapeuticsN/AGBX 2.72-4.7%N/A+77.9%£26.79M£20.92M-0.7040,000Gap UpELXEl OroN/AN/AN/AN/A£41.06M-£7.25M-26.001,122News CoverageTAOTAO AlphaN/AGBX 8-11.1%N/A+1,320.0%£30.30MN/A-32.503Positive NewsEarnings ReportGap UpHigh Trading VolumeAPCApc Technology GroupN/AN/AN/AN/A£18.03M£19.20M19.75164,000DGIDG InnovateN/AN/AN/AN/A£1.90M£24.50K-1.25790Gap DownIDEAIdeagenN/AN/AN/AN/A£1.03B£75.28M17,450.009VLGVenture Life GroupN/AGBX 50.30-0.4%N/A+31.8%£64.10M£51.77M85.36165News CoveragePositive NewsEarnings ReportDNLDiurnal GroupN/AN/AN/AN/A£46.33M£4.68M-3.2133EAHECO Animal Health GroupN/AGBX 62.94+1.5%N/A-53.3%£42.65M£89.44M40.69234News CoveragePXSProvexisN/AGBX 0.59-4.1%N/A+45.4%£13.85M£846.98K-22.374Positive NewsGap UpCHLLChill Brands GroupN/AN/AN/AN/A£10.89M£624.19K-215.007 Related Companies and Tools Related Companies ELX Competitors TAO Competitors APC Competitors DGI Competitors IDEA Competitors VLG Competitors DNL Competitors EAH Competitors PXS Competitors CHLL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:STX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shield Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Shield Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
